Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 6Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1CNS 1

Conditions

Stomach Neoplasms 7Colorectal Neoplasms 6Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Pancreatic Neoplasms 3Gallbladder Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Prostatic Neoplasms 1Oesophagogastric Cancer 1Head and Neck Neoplasms 1HER2 Positive Esophagogastric Cancer 1Gastrointestinal Neoplasms 1GastroEsophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Dysgerminoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 50Cyclophosphamide 25Carboplatin 25Gemcitabine 20Cisplatin 19fludarabine 18Nivolumab 17Paclitaxel 16Bevacizumab 15Specimen Handling 14Fluorouracil 11Magnetic Resonance Spectroscopy 10aldesleukin 9Oxaliplatin 9Irinotecan 9Docetaxel 9Biopsy 9olaparib 8Trastuzumab 8durvalumab 7atezolizumab 7Hyperthermic Intraperitoneal Chemotherapy 7Albumin-Bound Paclitaxel 7Taxes 6Leucovorin 6Ipilimumab 6Interleukin-2 6Cetuximab 6Capecitabine 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Lapatinib × Gastrointestinal × Clear all
NCT00313599 2014-07-02

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

University of California, San Francisco

Phase 1 Completed
28 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Dysgerminoma, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Central Nervous System Neoplasms

NCT00447226 2012-06-12

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

GlaxoSmithKline

Phase 2 Terminated
32 enrolled 10 charts
GastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡